Search
brodalumab (Siliq)
Indications:
- moderate-severe psoriasis (FDA-approved Feb 2017)
- psoriatic arthritis
- may be used in conjunction with methotrexate &/or glucocorticoids [2]
Dosage:
- injection: 70-280 mg
- psoriatic arthritis:
- 140-280 mg weekly for 1st 2 weeks, then every 2 weeks
* 210 mg SC at weeks 0, 1, & 2, the 210 mg SC every 2 weeks [3]
* continued treatment beyond 16 weeks in patients who have not achieved an adequate response is not indicated [3]
Adverse effects:
- dose-dependent neutropenia (reversible)
Mechanism of action:
- IL17 receptor A antibody (IgG2 Ab)
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
dermatologic agent
receptor antagonist
References
- Papp KA et al.
Brodalumab, an anti-interleukin-17-receptor antibody for
psoriasis.
N Engl J Med 2012 Mar 29; 366:1181.
PMID: 22455412
- Mease PJ et al.
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic
arthritis.
N Engl J Med 2014 Jun 12; 370:2295
PMID: 4918373
- Lowes R
FDA Approves Siliq for Psoriasis.
Medscape. Feb 15, 2017.
http://www.medscape.com/viewarticle/875859
- FDA News Release. February 15, 2017
FDA approves new psoriasis drug
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm541981.htm
- Windle ML.
FDA New Drug and Biologic Approvals -- 2017 Year-in-Review
Medscape - Jan 11, 2018.
https://reference.medscape.com/viewarticle/890871
- U.S. Food and Drug Administration.
Novel Drug Approvals for 2017.
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm
- Lebwohl M, Strober B, Menter A et al
Phase 3 Studies Comparing Brodalumab with Ustekinumab in
Psoriasis.
N Engl J Med. 2015 Oct;373(14):1318-28.
PMID: 26422722 Free Article